Study Summary
This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.
Want to learn more about this trial?
Request More InfoInterventions
8/12-Day Production of Car-T CellsBIOLOGICAL
A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
8/12-Day Production of Cryopreserved Car-T CellsBIOLOGICAL
A fixed cryopreserved dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
12-Day Production of Car-T CellsBIOLOGICAL
A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Medical College of Wisconsin and Froedtert Hospital | Milwaukee | Wisconsin | United States |